Compare ARDX & STGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDX | STGW |
|---|---|---|
| Founded | 2007 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | STGW |
|---|---|---|
| Price | $5.98 | $5.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $10.65 | $8.46 |
| AVG Volume (30 Days) | ★ 2.7M | 1.7M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1954.71 |
| EPS | N/A | ★ 0.06 |
| Revenue | $398,234,000.00 | ★ $2,890,264,000.00 |
| Revenue This Year | $22.71 | $4.53 |
| Revenue Next Year | $27.81 | $7.81 |
| P/E Ratio | ★ N/A | $100.74 |
| Revenue Growth | ★ 58.12 | 6.75 |
| 52 Week Low | $3.21 | $4.03 |
| 52 Week High | $6.78 | $7.96 |
| Indicator | ARDX | STGW |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 63.86 |
| Support Level | $5.49 | $5.19 |
| Resistance Level | $6.02 | $5.44 |
| Average True Range (ATR) | 0.28 | 0.21 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 75.00 | 97.25 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.